Marshall Wace
BIOS

Marshall Wace’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Marshall Wace’s Portfolio BIOS Stock Details BIOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-502,350
Closed -$5.16M – 3344
2022
Q4 		$5.16M Hold
502,350
– – 0.01% 1162
2022
Q3 		$5.05M Buy
502,350
+120,000
+31% +$1.2M 0.01% 1364
2022
Q2 		$3.84M Buy
382,350
+2,050
+0.5% +$20.4K 0.01% 1548
2022
Q1 		$3.76M Buy
+380,300
New +$3.75M 0.01% 1610

Other funds holding BIOS

AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 51.46% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace's BIOS Position: Q1 2023 in Review

Marshall Wace sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q1 2023, closing a stake of 502,350 shares — an estimated $5.16M sold.

Marshall Wace first reported a position in BIOS in Q1 2022 and held it in 4 quarters. The position peaked at $5.16M in Q4 2022. 61 funds tracked by Wall St. Rank hold BIOS as of Q1 2023.

  • Marshall Wace reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • Marshall Wace sold 502,350 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $5.16M.
  • Marshall Wace first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 4 quarters.
  • Marshall Wace's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $5.16M in Q4 2022.
  • 61 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.